Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo aims to boost bladder cancer surgery outcomes

NCT ID NCT03924895

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding two immunotherapy drugs—pembrolizumab and enfortumab vedotin—before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. The study includes patients who cannot take or choose not to take the standard chemotherapy drug cisplatin. Participants are randomly assigned to receive either surgery alone, surgery plus pembrolizumab, or surgery plus both drugs. The main goal is to see if the drug combinations improve event-free survival compared to surgery alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pembrolizumab and Enfortumab Vedotin
What this could lead to
If successful, this combination could offer a more effective treatment option for people with muscle-invasive bladder cancer who cannot tolerate standard chemotherapy, potentially delaying or preventing cancer return.
What could go wrong
This is an early-phase trial, and the added drugs may cause side effects like immune reactions or nerve damage. It is not yet known if the combination is better than surgery alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

595 people

The number who actually took part.

Started

Jul 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a histologically confirmed diagnosis of urothelial carcinoma/muscle-invasive bladder cancer \[MIBC\] (cT2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology to be confirmed by Blinded Independent Central Review (BICR) (central pathology and/or imaging). * Clinically nonmetastatic bladder cancer determined by imaging * Eligible for radical cystectomy (RC) + pelvic lymph node dissection (PLND), and agreement to undergo curative intent standard RC + PLND (including prostatectomy if applicable) * Ineligible for treatment with cisplatin, as defined by meeting at least one of the following criteria OR be eligible for treatment with cisplatin but decline treatment with cisplatin-based chemotherapy: * Impaired renal function with measured or calculated creatinine clearance (CrCl) 30 to 59 mL/min (calculated by Cockcroft-Gault method, Modification of Diet of Renal Disease \[MDRD\] equations, or measured by 24-hour urine collection) * Eastern Cooperative Oncology Group (ECOG) Performance Status 2 * Common Terminology Criteria for Adverse Events (CTCAE) v.4 Grade ≥2 audiometric hearing loss * New York Heart Association (NYHA) Class III heart failure * Transurethral resection (TUR) of a bladder tumor that is submitted for central pathology assessment and adequate to determine urothelial histology and PD-L1 expression assessment * ECOG performance status of 0, 1, or 2 * Adequate organ function * A male participant is eligible to participate if he agrees to use contraception and refrain from donating sperm during the intervention period and for at least 180 days after the last dose of enfortumab vedotin. If the male participants are receiving pembrolizumab only or undergoing surgery only, there are no contraception requirements * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a (woman of childbearing potential) WOCBP or a WOCBP who agrees to use a highly effective contraceptive method or be abstinent from heterosexual intercourse (as their preferred and usual lifestyle) during the intervention period and for at least 120 days after the last dose of pembrolizumab and at least 180 days after the last dose of enfortumab vedotin; whichever comes last. A female participant must agree not to donate eggs during this period as well * A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention Exclusion Criteria: * Known additional nonurothelial malignancy that is progressing or has required active anticancer treatment ≤3 years of study randomization, with certain exceptions * Has ≥ N2 or metastatic disease (M1) as identified by imaging * Received any prior systemic treatment, chemoradiation, and/or radiation therapy for muscle-invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) * Received prior therapy with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed cell death 1 ligand 2 (PD-L2), or with an agent directed to another stimulatory or coinhibitory T-cell receptor * Received prior systemic anticancer therapy including investigational agents within 3 years prior to randomization * Received any prior radiotherapy to the bladder * Received a partial cystectomy of the bladder to remove any non-muscle-invasive bladder cancer (NMIBC) or MIBC * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Current participation in or participation in a study of an investigational agent or use of an investigational device within 4 weeks prior to the first dose of study intervention * Ongoing sensory or motor neuropathy Grade 2 or higher * Diagnosis of immunodeficiency or receipt of chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency. * Hypersensitivity to monoclonal antibodies (including pembrolizumab) and/or any of their excipients * Severe hypersensitivity (≥ Grade 3) to enfortumab vedotin or any excipient contained in the drug formulation of enfortumab vedotin * Active keratitis or corneal ulcerations. Participants with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator * Active autoimmune disease that has required systemic therapy in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic therapy and is allowed * Has uncontrolled diabetes * History of (noninfectious) pneumonitis that required steroids, or current pneumonitis * Active infection requiring systemic therapy * Has had an allogeneic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary bladder cancer, muscle-invasive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urinary bladder cancer, muscle-invasive

Contacts and locations

Locations

  • A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559)

    Catania, 95123, Italy

  • AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 0562)

    Vicenza, Veneto, 36100, Italy

  • AZ Delta vzw-Oncology ( Site 0362)

    Roeselare, West-Vlaanderen, 8800, Belgium

  • AZ Maria Middelares Gent ( Site 0353)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • AZ Sint-Jan Brugge ( Site 0352)

    Bruges, West-Vlaanderen, 8000, Belgium

  • Aarhus University Hospital Skejby ( Site 0418)

    Aarhus, Central Jutland, 8200, Denmark

  • Abramson Cancer Center of the University of Pennsylvania ( Site 0074)

    Philadelphia, Pennsylvania, 19104, United States

  • Akademiska Sjukhuset ( Site 1211)

    Uppsala, Uppsala County, 751 85, Sweden

  • Allegheny General Hospital ( Site 0048)

    Pittsburgh, Pennsylvania, 15212, United States

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0100)

    Calgary, Alberta, T2N 5G2, Canada

  • Asan Medical Center ( Site 1355)

    Songpagu, Seoul, 05505, South Korea

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 2102)

    Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina

  • Azienda Ospedaliera Santa Maria Terni-S.C. Oncologia Medica e Traslazionale ( Site 0564)

    Terni, 05100, Italy

  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga-SCDU Oncologia Medica ( Site 0563)

    Orbassano, Piedmont, 10043, Italy

  • Azienda USL 8 di Arezzo-Medical Oncology ( Site 0565)

    Arezzo, 52100, Italy

  • BC Cancer Vancouver-Clinical Trials Unit ( Site 0121)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001)

    Budapest, 1106, Hungary

  • Barts Health NHS Trust - St Bartholomew s Hospital ( Site 0725)

    London, London, City of, EC1A 7BE, United Kingdom

  • Bayandin Murmansk Regional Clinical Hospital ( Site 0859)

    Murmansk, Murmansk Oblast, 183057, Russia

  • Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1061)

    Bielsko-Biala, Silesian Voivodeship, 43-300, Poland

  • Bialostockie Centrum Onkologii ( Site 1072)

    Bialystok, Podlaskie Voivodeship, 15-027, Poland

  • Bon Secours St. Francis Health System ( Site 1572)

    Greenville, South Carolina, 29607, United States

  • C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0492)

    Rennes, Ille-et-Vilaine, 35033, France

  • C.H.U. Lyon Sud ( Site 0466)

    Pierre-Bénite, Rhone, 69310, France

  • CARTI Cancer Center ( Site 1577)

    Little Rock, Arkansas, 72205, United States

  • CHU Cochin ( Site 0475)

    Paris, 75014, France

  • CHU Hotel Dieu Nantes ( Site 0458)

    Nantes, Loire-Atlantique, 44093, France

  • CHU Jean Minjoz ( Site 0455)

    Besançon, Doubs, 25000, France

  • CHU UCL Namur Site de Godinne ( Site 0354)

    Yvoir, Namur, 5530, Belgium

  • CHU de Bordeaux- Hopital Saint Andre ( Site 0456)

    Bordeaux, Gironde, 33000, France

  • CHU de Montpellier - Hopital Saint-Eloi ( Site 0469)

    Montpellier, Herault, 34295, France

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105)

    Montreal, Quebec, H1T 2M4, Canada

  • CIUSSS de l'Estrie-CHUS ( Site 0106)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • CIUSSS du Saguenay-Lac-St-Jean ( Site 0116)

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Cairns Base Hospital ( Site 1257)

    Cairns, Queensland, 4870, Australia

  • Cancercentrum ( Site 1214)

    Umeå, Västerbotten County, 901 85, Sweden

  • Carolina Urologic Research Center ( Site 0062)

    Myrtle Beach, South Carolina, 29572, United States

  • Central Clinical Hospital with outpatient Clinic ( Site 0856)

    Moscow, Moscow, 121359, Russia

  • Centre Francois Baclesse ( Site 0459)

    Caen, Calvados, 14075, France

  • Centre Georges Francois Leclerc ( Site 0488)

    Dijon, Bourgogne-Franche-Comté, 21000, France

  • Centro Estatal de Cancerologia de Chihuahua ( Site 0254)

    Chihuahua City, 31000, Mexico

  • Centro de Tratamiento de Cancer ( Site 0266)

    Metepec, 52140, Mexico

  • Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0253)

    Monterrey, Nuevo León, 66269, Mexico

  • Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Charleston Area Medical Center ( Site 0023)

    Charleston, West Virginia, 25304, United States

  • Clatterbridge Oncology Centre ( Site 0731)

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Cleveland Clinic Main ( Site 1576)

    Cleveland, Ohio, 44195, United States

  • Clinic of Bashkortostan State Medical University ( Site 0873)

    Ufa, Baskortostan, Respublika, 450081, Russia

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2002)

    Bogotá, Bogota D.C., 111321, Colombia

  • Clinical Hospital Saint Luka ( Site 0867)

    Saint Petersburg, Sankt-Peterburg, 194044, Russia

  • Clinical Research Center Medic-R ( Site 1073)

    Poznan, Greater Poland Voivodeship, 60-848, Poland

  • Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council ( Site 0976)

    Kherson, Kherson Oblast, 73034, Ukraine

  • Dana-Farber Cancer Institute ( Site 1596)

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem Klinikai Kozpont ( Site 1006)

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Dokkyo Medical University Saitama Medical Center ( Site 2304)

    Koshigaya, Saitama, 3438555, Japan

  • Eastern Health ( Site 1255)

    Box Hill, Victoria, 3128, Australia

  • Emory School of Medicine ( Site 0006)

    Atlanta, Georgia, 30322, United States

  • Europejskie Centrum Zdrowia Otwock ( Site 1058)

    Otwock, Masovian Voivodeship, 05-400, Poland

  • Faculty of Medicine Siriraj Hospital ( Site 1452)

    Bangkok, Bangkok, 10700, Thailand

  • First Moscow State Medical University n.a. I.M.Sechenov ( Site 0884)

    Moscow, Moscow, 119991, Russia

  • First St. Petersburg State Medical University n.a. acad. I.P. Pavlov ( Site 0872)

    Saint Petersburg, Sankt-Peterburg, 197022, Russia

  • Fondazione Salvatore Maugeri IRCCS ( Site 0554)

    Pavia, 27100, Italy

  • Fox Chase Cancer Center ( Site 0055)

    Philadelphia, Pennsylvania, 19111, United States

  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 2003)

    Medellín, Antioquia, 050030, Colombia

  • Fundacion Valle del Lili- CIC-Fundacion Valle del Lili ( Site 2005)

    Cali, Valle del Cauca Department, 760032, Colombia

  • Fundación Cardiovascular de Colombia ( Site 2004)

    Piedecuesta, Santander Department, 681017, Colombia

  • Georgetown University Medical Center ( Site 0022)

    Washington D.C., District of Columbia, 20007, United States

  • Gifu University Hospital ( Site 2310)

    Gifu, 501-1112, Japan

  • Greater Baltimore Medical Center ( Site 0014)

    Baltimore, Maryland, 21204, United States

  • Groote Schuur Hospital ( Site 1602)

    Cape Town, Western Cape, 7925, South Africa

  • Ha Emek Medical Center ( Site 0843)

    Afula, 1834111, Israel

  • Hacettepe Universitesi Tıp Fakultesi ( Site 0931)

    Ankara, 06100, Turkey (Türkiye)

  • Hadassah Ein Kerem Medical Center ( Site 0841)

    Jerusalem, 9112001, Israel

  • Hamamatsu University Hospital ( Site 2311)

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Herlev og Gentofte Hospital. ( Site 0412)

    Herlev, Capital Region, 2730, Denmark

  • Hoag Memorial Hospital Presbyterian ( Site 1595)

    Newport Beach, California, 92663, United States

  • Hopital Belle Isle ( Site 0452)

    Vantoux, Moselle, 57070, France

  • Hopital Bichat du Paris ( Site 0462)

    Paris, 75018, France

  • Hopital Europeen Georges Pompidou ( Site 0476)

    Paris, 75015, France

  • Hopital de la Timone ( Site 0489)

    Marseille, Bouches-du-Rhone, 13005, France

  • Hosp. Gral. Universitari Germans Trias i Pujol ( Site 0675)

    Badalona, Barcelona, 08916, Spain

  • Hospital Angeles Roma ( Site 0262)

    Mexico City, 06700, Mexico

  • Hospital Clinic i Provincial ( Site 0674)

    Barcelona, Catalonia, 08036, Spain

  • Hospital Pulau Pinang ( Site 1703)

    George Town, Pulau Pinang, 10990, Malaysia

  • Hospital San Pedro de Alcantara ( Site 0697)

    Cáceres, Extremadura, 10003, Spain

  • Hospital Universitario Quiron Madrid ( Site 0694)

    Pozuelo de Alarcón, Madrid, Comunidad de, 28223, Spain

  • Hospital Universitario Ramon y Cajal ( Site 0691)

    Madrid, 28034, Spain

  • Hospital Universitario San Carlos ( Site 0678)

    Madrid, 28040, Spain

  • Hospital Universitario la Paz ( Site 0690)

    Madrid, 28046, Spain

  • Hospital de Nuestra Senora de Valme ( Site 0693)

    Seville, 41014, Spain

  • Hospital del Mar ( Site 0698)

    Barcelona, 08003, Spain

  • IMAT S.A.S ( Site 2001)

    Montería, Departamento de Córdoba, 230002, Colombia

  • Icahn School of Medicine at Mount Sinai ( Site 0031)

    New York, New York, 10029, United States

  • Imperial College Healthcare NHS Trust ( Site 0745)

    London, Hammersmith and Fulham, W6 8RF, United Kingdom

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center ( Site 0004)

    Indianapolis, Indiana, 46202, United States

  • Inova Schar Cancer Institute ( Site 0007)

    Fairfax, Virginia, 22031, United States

  • Institut Català d'Oncologia (ICO) - Girona ( Site 0700)

    Girona, Gerona, 17007, Spain

  • Institut Claudius Regaud IUCT Oncopole ( Site 0486)

    Toulouse, Haute-Garonne, 31059, France

  • Institut Gustave Roussy ( Site 0487)

    Villejuif, Val-de-Marne, 94800, France

  • Institut de Cancerologie du Gard - CHU Caremeau ( Site 0490)

    Nîmes, Gard, 30029, France

  • Institute of Science Tokyo Hospital ( Site 2303)

    Bunkyō, Tokyo, 113-8519, Japan

  • Instituto Nacional de Cancerologia. ( Site 0256)

    Mexico City, 14080, Mexico

  • Instituto Valenciano de Oncologia - IVO ( Site 0679)

    Valencia, Valenciana, Comunitat, 46009, Spain

  • Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300)

    Aguascalientes, 20010, Mexico

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0930)

    Istanbul, 34096, Turkey (Türkiye)

  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552)

    Naples, 80131, Italy

  • Istituto Nazionale Studio e Cura dei Tumori ( Site 0551)

    Milan, 20133, Italy

  • Ivanovo Regional Oncology Dispensary ( Site 0852)

    Ivanovo, Ivanovo Oblast, 153040, Russia

  • Jewish General Hospital ( Site 0120)

    Montreal, Quebec, H3T 1E2, Canada

  • John H. Stroger Jr. Hospital of Cook County ( Site 1551)

    Chicago, Illinois, 60612, United States

  • John Wayne Cancer Institute ( Site 0075)

    Santa Monica, California, 90404, United States

  • Kagoshima University Hospital ( Site 2317)

    Kagoshima, 890-8520, Japan

  • Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0924)

    Trabzon, 61080, Turkey (Türkiye)

  • Karolinska Universitetssjukhuset Solna ( Site 1212)

    Stockholm, Stockholm County, 171 76, Sweden

  • Kent and Canterbury Hospital ( Site 0733)

    Canterbury, England, CT1 3NG, United Kingdom

  • Kitasato University Hospital ( Site 2306)

    Sagamihara, Kanagawa, 252-0375, Japan

  • Klinikum Stuttgart - Katharinenhospital ( Site 0520)

    Stuttgart, Baden-Wurttemberg, 70174, Germany

  • Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0549)

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Klinikum der Universitaet Muenchen - Grosshadern ( Site 0548)

    Munich, Bavaria, 81377, Germany

  • Korea University Anam Hospital ( Site 1351)

    Seoul, 02841, South Korea

  • Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861)

    Krasnoyarsk, Krasnoyarsk Krai, 660133, Russia

  • Kursk Regional Clinical Oncology Dispensary ( Site 0854)

    Kursk, Kursk Oblast, 305524, Russia

  • Kyiv City Clinical Oncology Center ( Site 0960)

    Kyiv, 03115, Ukraine

  • Kyungpook National University Chilgok Hospital-Urology ( Site 1357)

    Deagu, Taegu-Kwangyokshi, 41404, South Korea

  • Laenssjukhuset Ryhov ( Site 1215)

    Jönköping, Jönköping County, 551 85, Sweden

  • Leningrad Regional Oncology Center ( Site 0868)

    Saint Petersburg, Sankt-Peterburg, 188663, Russia

  • Lister Hospital ( Site 0739)

    Stevenage, Hertfordshire, SG1 4AB, United Kingdom

  • Luxmed Onkologia sp. z o. o. ( Site 1051)

    Warsaw, Masovian Voivodeship, 01-748, Poland

  • Lviv State Regional Oncological Center ( Site 0967)

    Lviv, Lviv Oblast, 79031, Ukraine

  • M Health Fairview Ridges Hospital ( Site 1555)

    Burnsville, Minnesota, 55337, United States

  • ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 0963)

    Dnipropetrovsk, Dnipropetrovsk Oblast, 49005, Ukraine

  • MNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of CRC" ( Site 0959)

    Cherkasy, Cherkasy Oblast, 18009, Ukraine

  • MNPE City Clinical Hospital #4 of Dnipro Regional Council ( Site 0951)

    Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine

  • MNPE Lviv Regional Clinical Hospital of Lviv Regional Council ( Site 0955)

    Lviv, Lviv Oblast, 79010, Ukraine

  • MNPE V.I. Shapoval Regional Medical Clinical Urology and Nephrology Center of KharkivRegCouncil ( Site 0969)

    Kharkiv, Kharkiv Oblast, 61037, Ukraine

  • Macquarie University ( Site 1251)

    Macquarie Park, New South Wales, 2109, Australia

  • Maharaj Nakorn Chiangmai Hospital ( Site 1453)

    Chiang Mai, 50200, Thailand

  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0921)

    Istanbul, 34899, Turkey (Türkiye)

  • Mater Misericordiae Ltd ( Site 1258)

    South Brisbane, Queensland, 4101, Australia

  • McGill University Health Centre ( Site 0123)

    Montreal, Quebec, H4A 3J1, Canada

  • Medical Sanitary Unit Neftyannik ( Site 0888)

    Tyumen, Tyumen Oblast, 625000, Russia

  • Meir Medical Center ( Site 0846)

    Kfar Saba, 4428164, Israel

  • MidLantic Urology ( Site 0089)

    Bala-Cynwyd, Pennsylvania, 19004, United States

  • Monash Health ( Site 1260)

    Clayton, Victoria, 3168, Australia

  • Moncton Hospital - Horizon Health Network ( Site 0112)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Morristown Medical Center ( Site 0015)

    Morristown, New Jersey, 07960, United States

  • Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0973)

    Kharkiv, Kharkiv Oblast, 61166, Ukraine

  • Nagano Municipal Hospital ( Site 2309)

    Tomitake, Nagano, 381-8551, Japan

  • Nagasaki University Hospital ( Site 2315)

    Nagasaki, 852-8501, Japan

  • Nara Medical University Hospital ( Site 2312)

    Kashihara, Nara, 634-0813, Japan

  • National Cancer Center ( Site 1354)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital East ( Site 2305)

    Kashiwa, Chiba, 277-8577, Japan

  • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 0860)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • National University Hospital ( Site 1802)

    Singapore, Central Singapore, 119074, Singapore

  • Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0929)

    Konya, 42080, Turkey (Türkiye)

  • New England Cancer Specialists ( Site 0070)

    Westbrook, Maine, 04092, United States

  • New York University Perlmutter Cancer Center ( Site 0008)

    New York, New York, 10016, United States

  • Northwell Health - Monter Cancer Center ( Site 0083)

    Lake Success, New York, 11042, United States

  • Odense Universitetshospital ( Site 0413)

    Odense, Region Syddanmark, 5000, Denmark

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)

    Tulsa, Oklahoma, 74146, United States

  • Omsk Clinical Oncology Dispensary ( Site 0865)

    Omsk, Omsk Oblast, 644013, Russia

  • Onkologiska kliniken ( Site 1217)

    Gothenburg, Västra Götaland County, 413 45, Sweden

  • Osaka Rosai Hospital ( Site 2320)

    Sakai, Osaka, 591-8025, Japan

  • Ospedale San Raffaele-Oncologia Medica ( Site 0561)

    Milan, 20132, Italy

  • Parkview Cancer Institute ( Site 0077)

    Fort Wayne, Indiana, 46845, United States

  • Petz Aladar Megyei Oktato Korhaz ( Site 1012)

    Győr, 9023, Hungary

  • Policlinico Gemelli di Roma ( Site 0558)

    Roma, Abruzzo, 00168, Italy

  • Princess Margaret Cancer Centre ( Site 0107)

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Portland Medical Center [Portland, OR] ( Site 0095)

    Portland, Oregon, 97213, United States

  • Rabin Medical Center ( Site 0847)

    Petah Tikva, 4941492, Israel

  • Ramathibodi Hospital. ( Site 1451)

    Bangkok, Bangkok, 10400, Thailand

  • Rambam Health Care Campus-Oncology Division ( Site 0845)

    Haifa, 3109601, Israel

  • Regional Oncology Center of Kharkiv ( Site 0958)

    Kharkiv, Kharkiv Oblast, 61000, Ukraine

  • Rigshospitalet University Hospital ( Site 0411)

    Copenhagen, Capital Region, 2100, Denmark

  • Royal Cornwall Hospital ( Site 0727)

    Truro, TR1 3LJ, United Kingdom

  • Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 0878)

    Moscow, Moscow, 115478, Russia

  • SNPE National Cancer Institute ( Site 0962)

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 0533)

    Gera, Thuringia, 07548, Germany

  • SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010)

    Szeged, Csongrád megye, 6720, Hungary

  • Saitama Prefectural Cancer Center ( Site 2319)

    Ina-machi, Saitama, 362-0806, Japan

  • Sakarya Universitesi Tip Fakultesi ( Site 0933)

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center ( Site 1353)

    Seoul, 06351, South Korea

  • Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866)

    Saratov, Saratov Oblast, 410012, Russia

  • Sarawak General Hospital ( Site 1701)

    Kuching, Sarawak, 93586, Malaysia

  • Scripps MD Anderson ( Site 0010)

    La Jolla, California, 92037, United States

  • Seoul National University Bundang Hospital ( Site 1356)

    Seongnam-si, Kyonggi-do, 13620, South Korea

  • Seoul National University Hospital ( Site 1352)

    Seoul, 03080, South Korea

  • Shaare Zedek Medical Center ( Site 0842)

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0844)

    Ramat Gan, 5265601, Israel

  • Silverado Resarch Inc. ( Site 0111)

    Victoria, British Columbia, V8T 2C1, Canada

  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007)

    Kaposvár, 7400, Hungary

  • Soroka Medical Center ( Site 0849)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 0850)

    Tel Aviv, 6423906, Israel

  • Srinagarind Hospital ( Site 1454)

    Khon Kaen, 40002, Thailand

  • St. Joseph Heritage Healthcare ( Site 0046)

    Fullerton, California, 92835, United States

  • St. Luke s Medical Center ( Site 1751)

    Quezon City, National Capital Region, 1112, Philippines

  • St. Marianna University Hospital ( Site 2321)

    Kawasaki, Kanagawa, 216-8511, Japan

  • Steve Biko Academic Hospital-Medical Oncology ( Site 1601)

    Pretoria, Gauteng, 0001, South Africa

  • Sunnybrook Research Institute ( Site 0110)

    Toronto, Ontario, M4N 3M5, Canada

  • Sverdlovsk Regional Oncology Hospital ( Site 0874)

    Yekaterinburg, Sverdlovsk Oblast, 620036, Russia

  • Szpital Wojewodzki ( Site 1062)

    Tarnów, Lesser Poland Voivodeship, 33-100, Poland

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0926)

    Istanbul, 34722, Turkey (Türkiye)

  • THE MEDICAL CITY ILOILO ( Site 1756)

    Iloilo City, Iloilo, 5000, Philippines

  • Tallaght University Hospital ( Site 0734)

    Dublin, D24 NR0A, Ireland

  • Tan Tock Seng Hospital ( Site 1804)

    Singapore, Central Singapore, 398442, Singapore

  • Texas Oncology-Baylor Sammons Cancer Center ( Site 1552)

    Dallas, Texas, 75246, United States

  • The James Cook University Hospital ( Site 0730)

    Middlesbrough, England, TS4 3BW, United Kingdom

  • The Medical City ( Site 1752)

    Pasig, National Capital Region, 1605, Philippines

  • The Royal Marsden Foundation Trust ( Site 0726)

    London, London, City of, SW3 6JJ, United Kingdom

  • Thomas Jefferson University ( Site 1579)

    Philadelphia, Pennsylvania, 19107, United States

  • Tohoku University Hospital ( Site 2301)

    Sendai, Miyagi, 980-8574, Japan

  • Toranomon Hospital ( Site 2322)

    Minato-ku, Tokyo, 105-8470, Japan

  • Toyama University Hospital ( Site 2308)

    Toyoma, Toyama, 930-0194, Japan

  • Tulane University School of Medicine ( Site 0088)

    New Orleans, Louisiana, 70112, United States

  • UCL Saint-Luc - Oncologie Medicale ( Site 0357)

    St-Lambrechts-Woluwe, Bruxelles-Capitale, Region de, 1200, Belgium

  • UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045)

    Albuquerque, New Mexico, 87106, United States

  • UZ Leuven ( Site 0361)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Universitaetsklinikum Bonn ( Site 0550)

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitaetsklinikum Carl Gustav Carus ( Site 0532)

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Erlangen ( Site 0546)

    Erlangen, Bavaria, 91058, Germany

  • Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0528)

    Hamburg, 20246, Germany

  • Universitaetsklinikum Magdeburg A.o.R. ( Site 0535)

    Magdeburg, Saxony-Anhalt, 39120, Germany

  • Universitaetsklinikum Wuerzburg ( Site 0547)

    Würzburg, Bavaria, 97080, Germany

  • University Hospital Waterford ( Site 0747)

    Waterford, X91ER8E, Ireland

  • University Malaya Medical Centre ( Site 1702)

    Lembah Pantai, Kuala Lumpur, 59100, Malaysia

  • University of Chicago ( Site 0068)

    Chicago, Illinois, 60637, United States

  • University of Colorado Hospital ( Site 0098)

    Aurora, Colorado, 80045, United States

  • University of South Alabama, Mitchell Cancer Institute ( Site 1582)

    Mobile, Alabama, 36604, United States

  • University of Tsukuba Hospital ( Site 2302)

    Tsukuba, Ibaraki, 305-8576, Japan

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1063)

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • Urology Associates [Nashville, TN] ( Site 0053)

    Nashville, Tennessee, 37209, United States

  • Vanderbilt University Medical Center ( Site 0017)

    Nashville, Tennessee, 37232, United States

  • Vivantes Klinikum am Urban ( Site 0529)

    Berlin, 10967, Germany

  • Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603074, Russia

  • Walsall Manor Hospital-Oncology ( Site 0743)

    Walsall, Devon, WS2 9PS, United Kingdom

  • Western General Hospital ( Site 0749)

    Edinburgh, Midlothian, EH4 2XU, United Kingdom

  • Western Sydney Local Health District ( Site 1259)

    Blacktown, New South Wales, 2148, Australia

  • Wichita Urology Group ( Site 0059)

    Wichita, Kansas, 67226, United States

  • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku ( Site 1057)

    Słupsk, Pomeranian Voivodeship, 76-200, Poland

  • Yitzhak Shamir Medical Center. ( Site 0848)

    Ẕerifin, 7033001, Israel

  • Yokosuka Kyosai Hospital ( Site 2307)

    Yokosuka, Kanagawa, 238-8558, Japan

  • Zhytomyr Regional Oncology Center ( Site 0971)

    Zhytomyr, Zhytomyr Oblast, 10002, Ukraine